IMPE Abstracts

The medical world has been undertreating youth onset type 2 diabetes for decades. With the number of youths affected by this devastating disease increasing worldwide there is no room in modern medicine for clinical inertia. Intensified therapy to treat-to-target rather than treat-to-failure is best practice. Clinicians caring for youth affected by type 2 diabetes need to be prepared to muster the courage and ask for early access to off-label medications....

Over the last two decades, there has been a major expansion in agents targeting contributors to metabolic dysfunction in type 2 diabetes. Modern pharmacologic agents have allowed clinicians to move beyond reduction in glycemia as the primary treatment target and to begin to select agents based on more individualized aspects of dysfunction unique to each patient. The potency of this approach is demonstrated by the changing outcomes landscape for adult individuals with type 2 di...